LifeStance Health Group (NASDAQ:LFST) Posts Earnings Results, Beats Expectations By $0.03 EPS

Key Points

• Q1 beat: LifeStance reported EPS of $0.04 (vs. $0.01 est.) and revenue of $403.5M (+21% YoY), and management raised Q2 and FY2026 revenue guidance, sparking a strong share rally.
• Capital actions & selling risk: The Board authorized a roughly $100M repurchase (≈3.6% of shares) even as selling stockholders launched a 35M‑share secondary and insiders sold about 4.39M shares recently, creating near‑term supply and volatility risk.
• Analyst sentiment: Multiple firms raised price targets and the consensus rating is "Buy" with an average target near $9.83.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03, Briefing.com reports. LifeStance Health Group had a return on equity of 0.65% and a net margin of 0.68%.The business had revenue of $403.48 million for the quarter, compared to analyst estimates of $387.46 million. The firm's quarterly revenue was up 21.2% on a year-over-year basis.

LifeStance Health Group Stock Performance

Shares of LFST stock traded up $1.49 during trading hours on Thursday, reaching $8.85. The stock had a trading volume of 13,778,238 shares, compared to its average volume of 4,296,210. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.65 and a quick ratio of 1.65. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $8.89. The firm has a 50-day simple moving average of $6.80 and a 200-day simple moving average of $6.68. The firm has a market capitalization of $3.43 billion, a PE ratio of 442.72 and a beta of 1.20.

LifeStance Health Group declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, February 25th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the company to buy up to 3.6% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board believes its stock is undervalued.

Insider Transactions at LifeStance Health Group

In other news, Director Darren M. Black sold 4,314,939 shares of LifeStance Health Group stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $7.01, for a total transaction of $30,247,722.39. Following the sale, the director owned 29,209,776 shares of the company's stock, valued at approximately $204,760,529.76. The trade was a 12.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert Bessler sold 62,147 shares of the business's stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of $7.05, for a total value of $438,136.35. Following the transaction, the director owned 1,274,448 shares of the company's stock, valued at approximately $8,984,858.40. This represents a 4.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 4,389,939 shares of company stock valued at $30,775,881 over the last three months. 3.20% of the stock is currently owned by company insiders.

Institutional Trading of LifeStance Health Group

Several hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its stake in shares of LifeStance Health Group by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company's stock worth $885,000 after purchasing an additional 1,966 shares in the last quarter. Vident Advisory LLC raised its stake in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company's stock valued at $112,000 after purchasing an additional 2,447 shares in the last quarter. Xponance LLC lifted its holdings in LifeStance Health Group by 26.4% in the fourth quarter. Xponance LLC now owns 13,144 shares of the company's stock worth $93,000 after purchasing an additional 2,745 shares during the period. Legal & General Group Plc lifted its holdings in LifeStance Health Group by 2.4% in the second quarter. Legal & General Group Plc now owns 144,263 shares of the company's stock worth $746,000 after purchasing an additional 3,331 shares during the period. Finally, Polar Capital Holdings Plc grew its position in LifeStance Health Group by 19.3% in the 3rd quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company's stock valued at $120,000 after buying an additional 3,525 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

Key LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q1 beat — LifeStance reported Q1 revenue of $403.5M (up ~21% YoY) and EPS of $0.04, both above consensus, which is driving the bullish reaction. Read More.
• Positive Sentiment: Raised revenue guidance — Management updated Q2 and FY2026 revenue ranges above Street revenue expectations (Q2: $405M–$425M; FY: ~$1.6B–$1.7B), supporting the stock rally by signaling continued top-line growth. Read More.
• Positive Sentiment: Board authorized a concurrent repurchase of up to 6M shares — the buyback can partially offset selling pressure from the secondary and is being highlighted as shareholder-friendly. Read More.
• Neutral Sentiment: Earnings call transcript and slide deck are available for detail — analysts and investors are parsing margins, clinician growth, and reimbursement commentary from the call. Read More.
• Negative Sentiment: Large secondary offering by existing stockholders: 35M shares will be sold by selling stockholders (LifeStance receives no proceeds). That raises near-term supply and volatility risk; heavy insider/related-party selling is noted in filings. Investors must weigh the selling pressure against the 6M-share repurchase. Read More. · Read More.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LFST. Canaccord Genuity Group boosted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. UBS Group raised their price target on shares of LifeStance Health Group from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Weiss Ratings raised shares of LifeStance Health Group from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, February 27th. Barclays boosted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an "overweight" rating in a research report on Friday, March 6th. Finally, KeyCorp increased their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $9.83.

About LifeStance Health Group

LifeStance Health Group NASDAQ: LFST is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.